Mayo Clinic Proceedings Home

Addition of an Anesthetic Agent to Enhance the Predictability of the Effects of Botulinum Toxin Type A Injections: A Randomized Controlled Study


      To determine whether the paralyzing effect of botulinum toxin type A reconstituted in a solution of lidocaine with epinephrine is as effective as that of the same toxin reconstituted in saline and to determine whether the addition of lidocaine with epinephrine enhances the predictability of outcomes of botulinum toxin injections.

      Subjects and Methods

      This double-blind, within-subject, randomized controlled study was conducted in 10 volunteer subjects. Lidocaine was added to botulinum toxin type A to achieve an immediate paralyzing effect on the injected muscle, and epinephrine was added to minimize diffusion of the injected toxin to adjacent muscles. This combination of agents was injected to temporarily paralyze the frontalis, corrugator supercilii, and procerus muscles on 1 side of the forehead of the 10 volunteers. The contralateral side was injected with the same dosage of the toxin, reconstituted in an equal volume of saline, to serve as control. Photographic and video docu- mentation of the drugs' effects was obtained before injection and at 5 to 10 minutes, 1 week, and 3 months after the injections.


      Immediate paralysis ensued on the experimental side (botulinum toxin type A + lidocaine + epinephrine) in all 10 volunteers. As assessed by 3 blinded evaluators, the extent of immediate paralysis resulting from the anesthetic agent was predictive of the extent of delayed paralysis resulting from the botulinum toxin. The botulinum toxin-induced paralysis wore off symmetrically in all subjects.


      The injection of botulinum toxin reconstituted in lidocaine with epinephrine provided the physician immediate feedback on the extent of paralysis to be expected from the chemodenervating action of the botuli- num toxin. This may enhance the safety and predictability of botulinum toxin injections in many applications.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Scon AB
        Botulinum toxin injection inlo extraocular muscles as an alternative to strabismus surgery.
        Ophthalmology. 1980; 87: I044-L049
        • Hallctt M
        One man's poison-clinical applications of bolulinum toxin (cdiloriall.
        NEngl JMed. 1999; 341: 118-120
        • Drobik C
        • Laskawi R
        Prey's syndrome: treatment with botulinum toxin.
        Ada Otolarxngol fStockh). 1995; 115: 459-461
        • Carruthers A
        • Carruthers J
        Aesthetic indications for botulinum toxin injections lletterl.
        Plast Reconstr Surg. 1995; 95: 427-428
        • Gassner HG
        • Sherris DA
        • Otley CC
        Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates.
        Plast Reconstr Surg. 2000; 105: 1948-1953
        • Shems DA
        • Larrabee Jr, WF
        • Murakami CS
        Management of scar contractures, hypertrophie scars, and keloids.
        Otolaryngol Clin North Am. 1995; 28: 1057-1068
        • Armstrong MW
        • Mountain RE
        • Murray JA
        Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy.
        Clin Ololaryngol. 1996; 21: 15-20
        • Brisinda G
        • Maria G
        • Bentivoglio AR
        • Cassetta E
        • Gui D
        • Albanese A
        A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure.
        N Engl J Med. 1999; 341: 65-69
        • Klein AW
        • Mantell A
        Electromyographic guidance in injecting botulinum toxin.
        Dermatol Surg. 1998; 24: 1184-1186
        • Blitzer A
        • Binder WJ
        • Aviv JE
        • Keen MS
        • Brin MF
        The management of hyperfunctional facial lines with botulinum toxin.
        Arch Otolaryngol Head Neck Surg. 1997; 123: 389-392
        • Poewe W
        • Deuschl G
        • Nebe A
        • et al.
        German Dystonia Study Group.
        What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? J Neurol Neurosurg Psychiatry. 1998; 64: 13-17
        • Gracies JM
        • Elovic E
        • McGuire J
        • Simpson DM
        Traditional pharmacological treatments for spasticity, part I: local treatments.
        Muscle Nerve Suppl. 1997; 6: S6l-S91
        • Karatassas A
        • Morris RG
        • Slavotinek AH
        The relationship between regional blood flow and absorption of lignocaine.
        Aust NZ J Surg. 1993; 63: 766-771
        • Wieder JM
        • Moy RL
        Understanding botulinum toxin: surgical anatomy of the frown, forehead, and periocular region.
        Dermatol Surg. 1998; 24: 1172-1174
        • Tardieu C
        • Tardieu G
        • Colbeau-Justin P
        • Huet de la Tour E
        • Lespargot A
        Trophic muscle regulation in children with congenital cerebral lesions.
        J Neurol Seci. 1979; 42: 357-364
        • Sherris DA
        • Kern EB
        Basic Surgical Skills. Mayo Clinic Scientific Press, Rochester, Minn1999: 21-22